Discover
CRVS
Corvus Pharmaceuticals, Inc.
14.06
2 x 14.04
2 x 14.08
bid
ask
-
0.41
2.85%
12:05 PM
timesize
| Ytd | 82.56% | |
| 1y | 224.65% |
13.94
day range
14.57
3.96
52 week range
26.95
| Open | 14.38 | Prev Close | 14.47 | Low | 13.94 | High | 14.57 | Mkt Cap | 1.22B |
| Vol | 177.09K | Avg Vol | 1.55M | EPS | -0.52 | P/E | -27.83 | Forward P/E | -16.55 |
| Beta | 0.82 | Short Ratio | 13.43 | Inst. Own | 85.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 13.39 | 200-d Avg | 12.71 | 1yr Est | 33.33 |
| Income Statement | |||
| Operating Expenses | 14.88M | ||
| Research and Development Expense | 11.18M | ||
| Selling, General and Administrative Expense | 3.70M | ||
| Operating Income | -14.88M | ||
| Net Income | -13.69M | ||
| Net Income Common Stock | -13.69M | ||
| Net Income Common Stock (USD) | -13.69M | ||
| Consolidated Income | -13.69M | ||
| Earnings per Basic Share | -0.15 | ||
| Earnings per Basic Share (USD) | -0.15 | ||
| Earnings per Diluted Share | -0.15 | ||
| Earning Before Interest & Taxes (EBIT) | -13.69M | ||
| Earning Before Interest & Taxes (USD) | -13.69M | ||
| Weighted Average Shares | 90.00M | ||
| Weighted Average Shares Diluted | 90.00M | ||
| Balance Sheet | |||
| Cash and Equivalents | 40.10M | ||
| Cash and Equivalents (USD) | 40.10M | ||
| Investments | 207.11M | ||
| Investments Current | 196.61M | ||
| Investments Non-Current | 10.50M | ||
| Trade and Non-Trade Receivables | 43.00K | ||
| Current Assets | 239.95M | ||
| Property, Plant & Equipment Net | 1.03M | ||
| Total Assets | 253.20M | ||
| Debt Current | 428.00K | ||
| Total Debt | 834.00K | ||
| Current Liabilities | 12.11M | ||
| Debt Non-Current | 406.00K | ||
| Total Liabilities | 12.52M | ||
| Accumulated Retained Earnings (Deficit) | -425.98M | ||
| Accumulated Other Comprehensive Income | -1.13M | ||
| Shareholders Equity | 240.68M | ||
| Shareholders Equity (USD) | 240.68M | ||
| Assets Non-Current | 13.25M | ||
| Total Debt (USD) | 834.00K | ||
| Liabilities Non-Current | 406.00K | ||
| Trade and Non-Trade Payables | 4.70M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 29.00K | ||
| Net Cash Flow from Financing | 190.75M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 35.53M | ||
| Capital Expenditure | -91.00K | ||
| Issuance (Purchase) of Equity Shares | 190.75M | ||
| Net Cash Flow from Investing | -144.85M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -144.75M | ||
| Net Cash Flow from Operations | -10.37M | ||
| Share Based Compensation | 2.65M | ||